Trial Profile
A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs MVA-p53 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions
- 18 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 17 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.